November 27, 2011


At the 2nd annual “Cancer Immunotherapy: A Long Awaited Reality” conference event in New York in October 2011, Craig's presentation opened with his describing Provectus treating cancer like an infectious disease.

Working from the premises that (a) a treatment must have immune system help and (b) the immune system will respond proportionally to the degree of insult or injury:
  • PV-10 has near absolute specificity when targeting diseased tissue and spares normal tissue. As a result, side effects are minimal and adverses events are nearly non-existent;
  • PV-10 removes tumors by multiple novel mechanism(s): Apoptosis-like on treated targets potentially combined with contributions by immune processes;
  • The intralesional delivery route produces a “vaccine/immunotherapy-like” systemic effect and enhances normal defenses;
  • PV-10 has a very wide range of activity (broad spectrum antibiotic-like); and,
  • It is reliable and the results are reproducible.
He then discussed new animal mechanism of action studies (below):

T cells do have something to do with PV-10's removal of remote tumors. Nude mice are athymic nudes, having intact immune systems except for T cells (i.e., B cells, NK cells, macrophages, dendritic cells, etc., but just not T cells). So, when PV-10 works in immunocompetent mice and not in nude mice, the outcome is due to the immune system, because it requires T cells. Provectus has repeated this over and over with different tumor types for melanoma, pancreatic, HCC, colorectal, etc.

The hallmarks of western science are predictability, verifiability and empiric repeatability. Craig's historical work has now been repeated by Moffitt. How well has it been repeated? To what level of success? You'll have to wait for the abstracts of immuno-studies #1 and #2 to be published.

I anticipate Moffitt's current animal studies this year and contemplated future animal and human studies next year should repeat more of Craig's work.

No comments:

Post a Comment